Information Provided By: 
Fly News Breaks for May 24, 2017
NBIX
May 24, 2017 | 06:34 EDT
JPMorgan analyst Anupam Rama says that while Neurocrine Biosciences' failed Phase 2 study of Ingrezza for pediatric Tourette syndrome is a "disappointing setback," expectations had been low going into the data readout based on the adult readout earlier this year. The "door remains open" to Tourette syndrome, Rama tells investors in a research note. He lowered his price target for Neurocrine shares to $57 from $60 and keeps an Overweight rating on the shares.
News For NBIX From the Last 2 Days
NBIX
Apr 23, 2024 | 10:29 EDT
